{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:54:56Z","timestamp":1758405296984,"version":"3.30.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.rmr.2024.08.004","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T03:17:32Z","timestamp":1728098252000},"page":"669-679","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacit\u00e9 des bioth\u00e9rapies de l\u2019asthme s\u00e9v\u00e8re sur les comorbidit\u00e9s allergiques"],"prefix":"10.1016","volume":"41","author":[{"given":"C.","family":"Thibaut de M\u00e9nonville","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Laborier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Le Brun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Dupin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Neukirch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Taill\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2024.08.004_bib0395","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2024.08.004_bib0400","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2147\/JAA.S402326","article-title":"Asthma prevalence and phenotyping in the general population: the LEAD (Lung, hEart, sociAl, boDy) study","volume":"16","author":"Schiffers","year":"2023","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.rmr.2024.08.004_bib0405","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13223-021-00598-3","article-title":"Epidemiology of comorbidities and their association with asthma control","volume":"17","author":"Tomisa","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0410","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaci.2006.11.639","article-title":"Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program","volume":"119","author":"Moore","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0415","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/cea.13613","article-title":"Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype","volume":"50","author":"Pelaia","year":"2020","journal-title":"Clin Exp Allergy J Br Soc Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0420","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.rmed.2019.06.004","article-title":"Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility","volume":"154","author":"Humbert","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2024.08.004_bib0425","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/all.12914","article-title":"Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment","volume":"71","author":"Magnan","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.rmr.2024.08.004_bib0430","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.anai.2018.01.030","article-title":"Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma","volume":"120","author":"Chipps","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0435","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1080\/02770903.2023.2185895","article-title":"Dupilumab long-term efficacy in patients with non-OCS-dependent asthma with and without evidence of allergic asthma","volume":"60","author":"Sher","year":"2023","journal-title":"J Asthma"},{"key":"10.1016\/j.rmr.2024.08.004_bib0440","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/cea.14256","article-title":"Efficacy of tezepelumab in patients with evidence of severe allergic asthma: results from the phase 3\u00a0NAVIGATOR study","volume":"53","author":"Corren","year":"2023","journal-title":"Clin Exp Allergy J Br Soc Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0445","first-page":"97","article-title":"Comorbidities & burden of disease in atopic dermatitis","volume":"41","author":"Gonzalez-Uribe","year":"2023","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0450","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41392-023-01344-4","article-title":"Pathogenesis of allergic diseases and implications for therapeutic interventions","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.rmr.2024.08.004_bib0455","doi-asserted-by":"crossref","first-page":"100519","DOI":"10.1016\/j.waojou.2021.100519","article-title":"Targeting immunoglobulin E in atopic dermatitis: a review of the existing evidence","volume":"14","author":"Wollenberg","year":"2021","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.rmr.2024.08.004_bib0460","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/all.15230","article-title":"Immunoglobulin E response in health and disease beyond allergic disorders","volume":"77","author":"Colas","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.rmr.2024.08.004_bib0465","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1440-1592.2000.00158.x","article-title":"Detection of anti-IgE anti-Fc\u025bRI \u03b1 chain auto-antibodies in patients with atopic dermatitis","volume":"49","author":"Hayashi","year":"2000","journal-title":"Allergol Int"},{"key":"10.1016\/j.rmr.2024.08.004_bib0470","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/imr.13367","article-title":"Mechanisms for initiation of food allergy by skin pre-disposed to atopic dermatitis","volume":"326","author":"Gao","year":"2024","journal-title":"Immunol Rev"},{"key":"10.1016\/j.rmr.2024.08.004_bib0475","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1111\/all.13971","article-title":"Risk of adult-onset asthma increases with the number of allergic multimorbidities and decreases with age","volume":"74","author":"Toppila-Salmi","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.rmr.2024.08.004_bib0480","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1542\/peds.111.3.608","article-title":"Atopic dermatitis and asthma: parallels in the evolution of treatment","volume":"111","author":"Eichenfield","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.rmr.2024.08.004_bib0485","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.rmed.2016.05.008","article-title":"Comorbidities of asthma in U.S. children","volume":"116","author":"Mirabelli","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2024.08.004_bib0490","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.anai.2023.08.021","article-title":"Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry","volume":"132","author":"Scelo","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0495","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/JAA.S424546","article-title":"Smoking, urban housing and work-aggravated asthma are associated with asthma severity in a cross-sectional observational study","volume":"17","author":"Chevereau-Choquet","year":"2024","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.rmr.2024.08.004_bib0500","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.jaci.2016.05.038","article-title":"Efficacy of omalizumab in patients with atopic dermatitis: a\u00a0systematic review and meta-analysis","volume":"138","author":"Wang","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0505","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/all.12234","article-title":"Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines","volume":"69","author":"Hotze","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.rmr.2024.08.004_bib0510","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamapediatrics.2019.4476","article-title":"Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial","volume":"174","author":"Chan","year":"2020","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.rmr.2024.08.004_bib0515","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/jdv.18345","article-title":"European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0520","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1398-9995.2005.00791.x","article-title":"Anti-IL-5\u00a0recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis","volume":"60","author":"Oldhoff","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.rmr.2024.08.004_bib0525","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/all.14050","article-title":"Efficacy and safety of mepolizumab administered subcutaneously for moderate to severe atopic dermatitis","volume":"75","author":"Kang","year":"2020","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.rmr.2024.08.004_bib0530","doi-asserted-by":"crossref","first-page":"e1211","DOI":"10.1111\/jdv.19195","article-title":"Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial","volume":"37","author":"Guttman-Yassky","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0535","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2024.08.004_bib0540","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3\u00a0trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2024.08.004_bib0545","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3\u00a0trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.rmr.2024.08.004_bib0550","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40257-020-00527-x","article-title":"Dupilumab provides favorable safety and sustained efficacy for up to 3\u00a0years in an open-label study of adults with moderate-to-severe atopic dermatitis","volume":"21","author":"Beck","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0555","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/ijd.16388","article-title":"Cutaneous T-cell lymphoma following dupilumab use: a systematic review","volume":"62","author":"Park","year":"2023","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0560","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40257-023-00804-5","article-title":"Dupilumab-associated arthritis: a dermatology-rheumatology perspective","volume":"24","author":"Woodbury","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0565","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0570","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0575","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaci.2017.11.051","article-title":"Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma","volume":"142","author":"Weinstein","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0580","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/alr.23090","article-title":"International consensus statement on allergy and rhinology: allergic rhinitis\u20132023","volume":"13","author":"Wise","year":"2023","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0585","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1067\/mai.2002.121949","article-title":"Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis","volume":"109","author":"Kuehr","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0590","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jaip.2014.02.001","article-title":"Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials","volume":"2","author":"Tsabouri","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rmr.2024.08.004_bib0595","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2332\/allergolint.55.379","article-title":"Omalizumab is effective and safe in the treatment of japanese cedar pollen-induced seasonal allergic rhinitis","volume":"55","author":"Okubo","year":"2006","journal-title":"Allergol Int"},{"key":"10.1016\/j.rmr.2024.08.004_bib0600","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1081-1206(10)62171-0","article-title":"Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis","volume":"91","author":"Chervinsky","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0605","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaci.2005.09.036","article-title":"Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis","volume":"117","author":"Casale","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0610","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.anai.2020.05.026","article-title":"Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis","volume":"125","author":"Busse","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0615","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2147\/JAA.S318892","article-title":"Short-term subcutaneous allergy immunotherapy and dupilumab are well tolerated in allergic rhinitis: a randomized trial","volume":"14","author":"Corren","year":"2021","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.rmr.2024.08.004_bib0620","first-page":"101072","article-title":"Dupilumab-induced rhinitis in severe asthma patients: a case series","volume":"85","author":"Fenech","year":"2024","journal-title":"Respir Med Res"},{"key":"10.1016\/j.rmr.2024.08.004_bib0625","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaci.2022.08.029","article-title":"Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial","volume":"151","author":"Corren","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0630","doi-asserted-by":"crossref","first-page":"100788","DOI":"10.1016\/j.waojou.2023.100788","article-title":"Vernal keratoconjunctivitis: current immunological and clinical evidence and the potential role of omalizumab","volume":"16","author":"Doan","year":"2023","journal-title":"World Allergy Organ J"},{"issue":"11","key":"10.1016\/j.rmr.2024.08.004_bib0635","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1016\/j.jaip.2023.07.016","article-title":"Omalizumab for severe allergic keratoconjunctivitis: a case series","volume":"11","author":"Mercier","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rmr.2024.08.004_bib0640","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1111\/jdv.16278","article-title":"Dupilumab therapy in a patient with atopic dermatitis and severe atopic keratoconjunctivitis","volume":"34","author":"Gkalpakiotis","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0645","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jaip.2019.10.011","article-title":"Amelioration of conjunctival giant papillae by dupilumab in patients with atopic keratoconjunctivitis","volume":"8","author":"Fukuda","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rmr.2024.08.004_bib0650","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/cea.13897","article-title":"The use of biologics in food allergy","volume":"51","author":"Fiocchi","year":"2021","journal-title":"Clin Exp Allergy J Br Soc Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0655","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jaip.2022.11.036","article-title":"Omalizumab in IgE-mediated food allergy: a systematic review and meta-analysis","volume":"11","author":"Zuberbier","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rmr.2024.08.004_bib0660","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/ACI.0000000000000900","article-title":"Biologicals in IgE-mediated food allergy","volume":"23","author":"Mutarelli","year":"2023","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0665","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jaip.2019.01.023","article-title":"Impact of omalizumab on food allergy in patients treated for asthma: a real-life study","volume":"7","author":"Fiocchi","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rmr.2024.08.004_bib0670","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2024.08.004_bib0675","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s12016-021-08902-0","article-title":"Combining Anti-IgE monoclonal antibodies and oral immunotherapy for the treatment of food allergy","volume":"62","author":"Guilleminault","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0680","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2468-1253(17)30392-8","article-title":"Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial","volume":"3","author":"Andorf","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0685","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jaci.2016.08.010","article-title":"Omalizumab facilitates rapid oral desensitization for peanut allergy","volume":"139","author":"MacGinnitie","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0690","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jaip.2018.07.027","article-title":"Dupilumab for treatment of food allergy","volume":"7","author":"Rial","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rmr.2024.08.004_bib0695","doi-asserted-by":"crossref","first-page":"159","DOI":"10.24920\/004208","article-title":"Dupilumab for treatment of food-dependent, exercise-induced anaphylaxis: report of one case","volume":"38","author":"Zhu","year":"2023","journal-title":"Chin Med Sci J"},{"key":"10.1016\/j.rmr.2024.08.004_bib0700","doi-asserted-by":"crossref","first-page":"137","DOI":"10.23822\/EurAnnACI.1764-1489.280","article-title":"Dupilumab to induce tolerance to SLIT-Melocot\u00f3n\u00ae","volume":"56","author":"Zamarro Parra","year":"2024","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0705","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaci.2017.05.006","article-title":"Safety and outcomes of aspirin desensitization for aspirin-exacerbated respiratory disease: a\u00a0single-center study","volume":"141","author":"Waldram","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0710","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/ACI.0000000000000648","article-title":"Omalizumab and other biologics in drug desensitization","volume":"20","author":"Fernandez","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0715","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jaci.2022.08.021","article-title":"Updates on immune mechanisms in aspirin-exacerbated respiratory disease","volume":"151","author":"Laidlaw","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0720","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.anai.2018.05.007","article-title":"Omalizumab can inhibit respiratory reaction during aspirin desensitization","volume":"121","author":"Lang","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0725","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.jaip.2023.04.033","article-title":"Nonsteroidal anti-inflammatory drug (NSAID) tolerance after biological therapy in patients with NSAID-exacerbated respiratory disease: a randomized comparative trial","volume":"11","author":"S\u00e1nchez","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rmr.2024.08.004_bib0730","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.jaip.2020.09.007","article-title":"Mepolizumab does not prevent all aspirin-induced reactions in patients with aspirin-exacerbated respiratory disease: a case series","volume":"9","author":"Martin","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rmr.2024.08.004_bib0735","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.anai.2019.06.012","article-title":"Mepolizumab utility in successful aspirin desensitization in aspirin-exacerbated respiratory disease in a refractory case","volume":"123","author":"Mahdavinia","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0740","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13223-020-00461-x","article-title":"Presence of positive skin prick tests to inhalant allergens and markers of T2\u00a0inflammation in subjects with chronic spontaneous urticaria (CSU): a systematic literature review","volume":"16","author":"Wong","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0745","doi-asserted-by":"crossref","first-page":"159","DOI":"10.24920\/004208","article-title":"Dupilumab for treatment of food-dependent, exercise-induced anaphylaxis: report of one case","volume":"38","author":"Zhu","year":"2023","journal-title":"Chin Med Sci J"},{"key":"10.1016\/j.rmr.2024.08.004_bib0750","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jaci.2022.06.027","article-title":"Novel biologics for treatment of chronic spontaneous urticaria","volume":"150","author":"Casale","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0755","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaci.2015.08.023","article-title":"Timing and duration of omalizumab response in patients with chronic idiopathic\/spontaneous urticaria","volume":"137","author":"Kaplan","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2024.08.004_bib0760","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/cts.13546","article-title":"The evolving landscape of immunotherapy for the treatment of allergic conditions","volume":"16","author":"Pandya","year":"2023","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.rmr.2024.08.004_bib0765","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/1945892419884774","article-title":"Clinical efficacy and safety of omalizumab in the treatment of allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials","volume":"34","author":"Yu","year":"2020","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.rmr.2024.08.004_bib0770","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1016\/j.jaip.2020.04.068","article-title":"Add-on omalizumab for inadequately controlled severe pollinosis despite standard-of-care: a randomized study","volume":"8","author":"Okubo","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.rmr.2024.08.004_bib0775","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2222.2008.03121.x","article-title":"Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma","volume":"39","author":"Kopp","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.rmr.2024.08.004_bib0390","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2332\/allergolint.55.379","article-title":"Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis","volume":"55","author":"Okubo","year":"2006","journal-title":"Allergol Int"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842524002742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842524002742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T03:56:13Z","timestamp":1732852573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842524002742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":78,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0761842524002742"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2024.08.004","relation":{},"ISSN":["0761-8425"],"issn-type":[{"type":"print","value":"0761-8425"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacit\u00e9 des bioth\u00e9rapies de l\u2019asthme s\u00e9v\u00e8re sur les comorbidit\u00e9s allergiques","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2024.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 SPLF. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}